Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial

Detalles Bibliográficos
Autores principales: Das, Sunit, Sahgal, Arjun, Perry, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005933/
https://www.ncbi.nlm.nih.gov/pubmed/32083011
http://dx.doi.org/10.3389/fonc.2020.00066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005933/
https://www.ncbi.nlm.nih.gov/pubmed/32083011
http://dx.doi.org/10.3389/fonc.2020.00066

Ejemplares similares